Nevro (NVRO) GF Score : 44/100 (As of Dec. 13, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Nevro GF Score?

Nevro has the GF Score of 44, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 2/10
3. Growth Rank : 1/10
4. GF Value Rank : 2/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Nevro might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Nevro's GF Score

For the Medical Devices subindustry, Nevro's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nevro's GF Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nevro's GF Score distribution charts can be found below:

* The bar in red indicates where Nevro's GF Score falls into.

Nevro (NYSE:NVRO) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Nevro GF Score Related Terms

Thank you for viewing the detailed overview of Nevro's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Nevro Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nevro Corp (NYSE:NVRO) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

1800 Bridge Parkway, Redwood City, CA, USA, 94065

Website

https://www.nevro.com

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

Executives

Greg Siller	officer: Chief Commercial Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Shawn Mccormick	director	9600-54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55441
Kevin R Thornal	officer: President & CEO	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Sridhar Kosaraju	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Elizabeth H Weatherman	director	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard B. Carter	officer: Chief Accounting Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Kashif Rashid	officer: General Counsel	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
D Keith Grossman	director, officer: President & CEO
Kevin C Oboyle	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Michael F Demane	director, officer: Chief Executive Officer	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Niamh Louise Pellegrini	officer: Chief Commercial Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Brad Vale	director	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Susan E Siegel	director	3000 SAND HILL ROAD, BLDG 3 STE 290, MENLO PARK CA 94025
Roderick H. Macleod	officer: Chief Financial Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Patrick Schmitz	officer: Vice President, Operations	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065